Safety and Efficacy of Gefitinib Administration After Osimertinib-Induced Interstitial Lung Disease: A Six-Case Series
Kaoruko Shimbu,Kakeru Hisakane,Naohiro Kadoma,Shunichi Nishima,Kenichiro Atsumi,Masahiro Seike,Takashi Hirose
DOI: https://doi.org/10.2147/ott.s475836
IF: 4
2024-09-01
OncoTargets and Therapy
Abstract:Kaoruko Shimbu, 1 Kakeru Hisakane, 1 Naohiro Kadoma, 1 Shunichi Nishima, 1 Kenichiro Atsumi, 1 Masahiro Seike, 2 Takashi Hirose 1 1 Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School, Tama Nagayama Hospital, Tokyo, 206-8512, Japan; 2 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, 113-8603, Japan Correspondence: Kakeru Hisakane, Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School, Tama Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo, 206-8512, Japan, Tel +81-42-371-2111, Email Purpose: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is the standard treatment for patients with non-small cell lung cancer harboring EGFR mutations. Although the frequency of osimertinib-induced interstitial lung disease (osi-ILD) is high, the optimal cancer treatment after osi-ILD has not been established. This time, we focused on the safety and efficacy of gefitinib following osi-ILD. Case Presentation: We experienced six cases (five women and one man; median age: 74 years) in which gefitinib was administered after osi-ILD. All six cases had grade 2 or higher osi-ILD and required steroid treatment. The computed tomography imaging pattern of osi-ILD revealed organizing pneumonia in three cases, diffuse alveolar damage in two cases, and hypersensitivity pneumonia in one case. Eastern Cooperative Oncology Group performance status was 1 in four cases, 2 in one case, and 3 in one case. EGFR mutation status was exon 19 deletion in two cases and exon 21 L858R in four cases. Only one patient experienced recurrence of ILD after receiving gefitinib. The best response to gefitinib was partial response in two cases and stable disease in three cases; one case was not evaluable. The median progression-free survival after treatment with gefitinib was 190 days (95% confidence interval: 33– 328). Conclusion: The treatment with gefitinib after the development of osi-ILD was safe and effective. Gefitinib may be a promising option for patients who recovered from severe osi-ILD. Keywords: chemotherapy, epidermal growth factor receptor kinase inhibitor, non-small cell lung cancer, steroid Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is recommended as a first-line treatment for patients with advanced non-small cell lung cancer harboring EGFR mutations. 1 Drug-induced interstitial lung disease (ILD) is a common adverse event of osimertinib. The reported probability of developing osimertinib-induced interstitial lung disease (osi-ILD) is 3.6%. 1 In the Japanese population, this probability ranges 12.3–18.3%. 2,3 In a real-world setting in Japan, the reported rate of osi-ILD was 6.8–17.7%. 4,5 Several successful cases of treatment with osimertinib or other EGFR-TKIs after osi-ILD have been reported. 6–13 A retrospective study evaluated the efficacy and safety of continued administration or re-administration of osimertinib after osi-ILD; however, most of these cases had grade 1 osi-ILD. 14 Thus far, few large-scale studies investigated the re-administration of EGFR-TKIs other than osimertinib after osi-ILD. Moreover, the optimal cancer treatment for patients who recovered from severe osi-ILD remains unclear. At our hospital, osimertinib was administered to 95 patients between June 1, 2016 and September 30, 2023. Thirteen patients developed osi-ILD, and six of those received gefitinib after osi-ILD; this report focuses on those six patients. In this article, we discuss the safety and efficacy of gefitinib based on the course of six cases. The date of data cut-off was March 31, 2024. The patient inclusion flowchart is illustrated in Figure 1. Figure 1 Patient inclusion flowchart. Notes : * One case in which osimertinib was re-administered prior to gefitinib administration. A 62-year-old Japanese woman with no history of smoking was diagnosed with stage IVB (cT4N3M1c) lung adenocarcinoma harboring the EGFR exon 19 deletion. Administration of osimertinib 80 mg daily was initiated as first-line treatment. However, osi-ILD occurred after 69 days, and treatment with osimertinib was discontinued. After administration of methylprednisolone 1000 mg for 3 days, post-therapy with prednisolone 40 mg was initiated. The patient had grade 3 osi-ILD, the maximal oxygen dose was 3 L with cannula, and computed tomography (CT) imaging showed an organizing pneumonia (OP) pattern (Figure 2). While discontinuing osimertinib, pleural effusion and lung metastasis increased. Therefore, after tapering the dose of predn -Abstract Truncated-
oncology,biotechnology & applied microbiology